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Objectives: To test the presumption that Pseudomonas aeruginosa isolates responsible for initial lung infection
in individuals with cystic fibrosis (CF) are invariably susceptible to antipseudomonal agents.
Methods: Antibiotic susceptibility was determined (MIC and Etest) in two populations of P. aeruginosa associ-
ated with initial lung infection. Population 1: environmental isolates (n¼78). Population 2: clinical isolates
responsible for first infection in previously non-infected patients (85 isolates from 85 patients). Susceptibility
or resistance was determined using current BSAC guidelines; ninth version (2009).
Results: The majority (≥90%) of isolates in both bacterial populations were susceptible to the front-line anti-
pseudomonal agents; colistin, ciprofloxacin, tobramycin, ceftazidime, amikacin and meropenem. Up to 10% of
isolates were resistant to one or more antibiotics. A single isolate from each population would be defined as
resistant to tobramycin based on a breakpoint (.128 mg/L) that has been suggested for use in patients receiv-
ing inhaled therapy.
Conclusions: The high prevalence of susceptibility found in P. aeruginosa isolates associated with initial infection
contrasts with the high prevalence of resistance found in isolates from chronic CF lung infection. However, sus-
ceptibility in early isolates cannot be presumed. Until further data are obtained from clinically based studies, sus-
ceptibility tests should continue to be performed to assist the choice of antibiotics for treatment of early infection.
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Introduction
Pseudomonas aeruginosa is the major bacterial pathogen
responsible for pulmonary failure in individuals with cystic fibrosis
(CF). Antibiotic therapy against P. aeruginosa plays an essential
role in the management of three stages of infection. First, in
early infection to prevent or delay transition to chronic infection;
second, in chronic infection to maintain lung function by redu-
cing pulmonary inflammation; and third, to treat acute pulmon-
ary exacerbations. Evidence that conventional antibiotic
susceptibility tests, including combination testing, are poorly pre-
dictive of clinical outcome in chronic infection challenges the jus-
tification for routine in vitro susceptibility testing.1–3
In a 5 year double-blind multicentred study, Aaron et al.2 com-
pared antibiotic choice for treatment of acute exacerbations,
using conventional susceptibility tests, with that based on mul-
tiple combination bactericidal testing. Disappointingly, the study
showed no difference in treatment outcome. Limitations of this
study were that susceptibility was based on previous sputum
isolates analysed within 3 months of the exacerbation, and that
participating centres used their own methodologies (not
described) for sputum culture and susceptibility testing. The
study also relied on local investigators to select isolates of
P. aeruginosa for testing. The issue of sampling is vital since varia-
bility in susceptibility between isolates of P. aeruginosa from the
same sputum, and even with the same colony morphotype, is
characteristic of chronic P. aeruginosa infection in CF.3,4
To date, concerns that conventional and biofilm-associated
antibiotic susceptibility tests do not predict clinical outcome
have focused on treatment of chronic P. aeruginosa infection
and associated and recurring pulmonary exacerbations. It is
not clear whether similar doubts should also apply to treatment
of early infection, which plays an increasingly important role in
clinical management following the early diagnosis of CF
through national newborn screening programmes. In the
absence or failure of early therapy, P. aeruginosa within the CF
lung evolves genomically and phenotypically over many years
to chronic infection, at which stage eradication is seldom
achieved. To our knowledge, there is no evidence that early
isolates of P. aeruginosa share the adaptation and phenotypic
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heterogeneity associated with chronic infection. It is also unclear
whether the lack of clinical value of susceptibility testing during
chronic infection also applies to treatment of early infection.
Current knowledge of the susceptibility of CF isolates of
P. aeruginosa is primarily based on chronic infection or acute
exacerbations. If early isolates are invariably susceptible to
antipseudomonal agents, the choice of antibiotics could be pre-
scriptive and made without recourse to the expense and time-
consuming process of susceptibility testing.
To test the presumption that P. aeruginosa isolates respon-
sible for initial infection of CF individuals are invariably suscep-
tible to front-line antipseudomonal agents, we investigated the
in vitro susceptibility of two populations of P. aeruginosa associ-
ated with early infection. Population 1 comprised P. aeruginosa
from natural environments. With the exception of sibling-to-
sibling transfer or epidemic spread, these are considered to be
the major source of early infection. Population 2 comprised clini-
cal isolates responsible for the first infection of CF patients.
Materials and methods
Bacteria
Population 1 comprised 78 environmental isolates of P. aeruginosa from
hospital and non-hospital environments (20 isolates and 58 isolates,
respectively); sites included sinks, drains, vegetables and ponds. Identifi-
cation was based on colony morphology, blue–green pigmentation and a
positive oxidase reaction. Presumptive non-pigmented isolates were
identified using API 20NE kits (bioMe´rieux, Marcy l’E´toile, France) and
species-specific PCR.5 Population 2 comprised 85 first P. aeruginosa
sputum isolates obtained during longitudinal studies from 85 CF patients
attending CF centres in the UK and Tuscany. Patients, aged 2 months to
40 years, had previously been Pseudomonas free and had not received
antipseudomonal treatment. All isolates examined exhibited a non-
mucoid colony morphotype and were selected for in the same manner
using Difco Pseudomonas isolation agar.
Within each population, clonality was excluded by PFGE. PFGE and
strain-specific PCR were also used to exclude known epidemic strains,
in particular the widespread Liverpool epidemic strain, LES. To exclude
heterogeneity in susceptibility in first isolates from the same sputum,
we examined a subset of 60 multiple colonies; these comprised 10 clon-
ally related colonies picked prospectively from the original sputum
samples from six patients.
Antibiotic susceptibility: MIC and Etest strips
The susceptibility of the two P. aeruginosa strain panels and multiple
colony subset to front-line antipseudomonal agents, namely colistin,
ciprofloxacin, tobramycin, ceftazidime, amikacin and meropenem, was
determined. MICs were determined by Etest (bioMe´rieux UK Ltd, Basing-
stoke, UK) according to the manufacturer’s instructions. Escherichia coli
ATCC 25922 and P. aeruginosa ATCC 27853 were used as controls for the
potency and breakpoints of the antibiotics used. Revised BSAC breakpoints
(Table 1) for Pseudomonas species were used to determine resistance as
follows: colistin, .2 mg/L; ciprofloxacin, .1 mg/L; ceftazidime, .8 mg/L;
tobramycin, .4 mg/L; amikacin, .16 mg/L; and meropenem, .8 mg/L.
Results
The degree of variability encountered for the ATCC control strains
and the P. aeruginosa panels was within the error of the test and
in no instance involved a change from susceptible to resistant, or
vice versa. Analysis of MICs showed that the majority (≥90%) of
isolates from environmental sites, and isolates responsible for
initial P. aeruginosa infection of CF patients, were susceptible to
each of the antipseudomonal antibiotics. However, according
to current breakpoints, up to 10% of isolates in both Pseudomo-
nas strain panels exhibited resistance to at least one antibiotic.
This included high-level (.256 mg/L) resistance to colistin in an
environmental isolate whose identification was confirmed.
Molecular typing indicated that sibling–sibling transfer or clon-
ality did not account for any of the resistance observed. There was
no significant difference in susceptibility between the two panels
of isolates to any of the antibiotics tested (x2 analysis,
P¼0.182). Multiresistance to two or more antibiotic classes was
rare. Interestingly, in both bacterial populations, we observed an
Table 1. Percentages of susceptible P. aeruginosa isolates and MIC ranges (mg/L) for environmental
and first CF isolates
Antimicrobial (resistance breakpoint)a Environmental isolates (n¼78) First CF isolates (n¼85)
Colistin (.2 mg/L) % susceptible 96 98
MIC range 0.25 to .256 1–4
Ciprofloxacin (.1 mg/L) % susceptible 96 96
MIC range 0.094–8 0.064 to .256
Ceftazidime (.8 mg/L) % susceptible 95 95
MIC range 0.5 to .256 0.75 to .256
Tobramycin (.4 mg/L) % susceptible 92 90
MIC range 0.38 to .256 0.38 to .256
Amikacin (.16 mg/L) % susceptible 97 93
MIC range 1 to .256 1 to .256
Meropenem (.8 mg/L) % susceptible 93 98
MIC range 0.032 to .32 0.064–16
aBased on BSAC guidelines, ninth version, 2009.
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isolate that would be defined as resistant to tobramycin based on
Etest and a breakpoint (.128 mg/L) that has been suggested for
predicting P. aeruginosa susceptibility to inhaled tobramycin.6 In
contrast to susceptibility testing of P. aeruginosa associated with
chronic infection, and outside the error of the test, examination
of multiple isolates from six individual sputa showed no evidence
of heterogeneity in the MICs for clonal isolates sampled from a
single sputum (data not shown).
Discussion
The microbiology of lung disease in patients with CF is complex.
Challenges include the need to explain why in vitro susceptibility
frequently fails to predict clinical efficacy, and the need to
appreciate that the terms susceptible and resistant are ill-
defined for chronic P. aeruginosa infections in individuals with
CF. In particular, conventional definition of resistance based on
breakpoints, serum drug concentrations, in vitro MICs and par-
enteral therapy does not apply to CF lung infections treated
with inhaled antibiotics.4
There has also been increasing interest in the cost-
effectiveness of antibiotic treatment for the different stages of
P. aeruginosa infection in CF. These studies have focused on
the costs of delivering antibiotics to CF patients either as outpa-
tients or in hospital; to our knowledge, the additional costs of
susceptibility testing have not been considered. However, in
one large UK CF clinic, a reduction in the number of routine sus-
ceptibility tests performed in cases of chronic P. aeruginosa
resulted in an annual saving on consumables and staff time of
10000 Euros without impact on short-term clinical outcomes.7
The present debate on the justification for routine susceptibility
testing in the management of CF lung infection has focused on
P. aeruginosa isolates responsible for chronic infection and pul-
monary exacerbations. The major objective of our study was to
test the presumption held by some clinicians and microbiologists
that P. aeruginosa populations responsible for early infection are
intrinsically susceptible to antipseudomonal agents. If our study
proved this presumption correct, it would provide preliminary evi-
dence that routine susceptibility testing might also be reduced in
the management of early infection. To our knowledge, such
an investigation has not been reported. One reason could be
the challenge of collecting and characterizing the necessary
P. aeruginosa strain panels critical for this study, and in particular
the panel of CF isolates responsible for initial infection that was
made possible by longitudinal studies of individual patients.
In our study, the in vitro susceptibility of P. aeruginosa, iso-
lated from environmental sites, or isolates responsible for initial
infection in CF patients, was reassuring, and with the exception
of colistin, contrasts with the disturbingly high resistance to anti-
pseudomonal agents reported in previous surveys.8
Although the majority of P. aeruginosa associated with initial
infection show in vitro susceptibility to front-line antipseudomo-
nal agents, our results indicate that susceptibility cannot be pre-
sumed. Two large multicentre studies focused on antibiotic
therapy of early P. aeruginosa infection merit consideration.
Interestingly, the recently published European ELITE study did
not address the potential role of susceptibility/resistance as a
reason for success or failure in bacterial eradication.9 Also,
although the North American EPIC study may provide data on
the emergence of antibiotic resistance, it does not include an
assessment of the validity of susceptibility testing.10
Clinical studies focused on early eradication of P. aeruginosa
are necessary to determine whether susceptibility testing per-
formed by conventional, biofilm-based methods or by a recently
described susceptibility breakpoint index8 correlate with clinical
outcomes, and to identify breakpoints that take account of the
high antibiotic concentrations achieved by aerosol delivery.
Until such information is available, it would seem prudent to con-
tinue susceptibility testing of P. aeruginosa responsible for early
infection in individuals with CF.
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